Figure 5. DFT-optimized geometry of (a) Baloxavir, (b) Oseltamivir, (c) Peramivir and (d) Zanamivir

From

Computational Insights into the Drug Repurposing and Synergism of FDA-approved Influenza Drugs Binding with SARS-CoV-2 Protease against COVID-19

Shazia Parveen, Rua B. Alnoman, Abrar A. Bayazeed, Alaa M. Alqahtani

American Journal of Microbiological Research. 2020, 8(3), 93-102 doi:10.12691/ajmr-8-3-3